Abstract Library

#4427 Surufatinib combined with hepatic artery infusion chemotherapy (HAIC) as second-line and maintenance therapy for neuroendocrine carcinoma with liver metastases: A single-arm, open-label, single-centre phase II clinical study (SuHaNec)

Introduction: Neuroendocrine carcinoma (NEC) is rare and highly aggressive, and liver metastasis leads to worse outcomes for patients (pts) with limited treatment options and poor prognosis. Surufatinib (SUR) exhibited promising antitumour activity in neuroendocrine neoplasms.

Conference:

Presenting Author:

Authors: Wang Y, Wang J, Yang D, Yao W, Zhang N,

Keywords: neuroendocrine carcinoma, surufatinib, hepatic artery infusion chemotherapy, later-line treatment,

#4247 Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia - A case report

Introduction: Idiopathic Diffuse Neuroendocrine Diffuse Neuroendocrine Hyperplasia is a rare, but increasingly recognized entity that primarily affects middle-aged and elderly women, Of available therapies, somatostatin analogs and mTOR are the most promising

Conference:

Presenting Author: Florez A

Authors: Florez A, Unigarro M, Fernandez J, Viola L, Perez G,

Keywords: neuroendocrine tumor, lung, idiopathic diffuse neuroendocrine hyperplasia, tumorlets,

#4239 Implementation of a new, nurse-led clinic (NLC) for neuroendocrine tumor (NET) patients

Introduction: There is international evidence supporting nurse-led services for people with chronic diseases in reducing hospitalisations, symptom improvement and lifestyle, and patient satisfaction. Patients with NET often have high symptoms burden and psychosocial distress in the context of indolent disease. Our centre recently implemented a (NLC) to provide complex care support for patients with NET.

Conference:

Presenting Author:

Authors: Wakelin K, Michael M, Kong G, Rogers M, Natkunarajah N,

Keywords: Nurse-led care, Multidisciplinary care, Supportive care, Symptom management, Patient support,

#4104 Promising outcomes with surufatinib-vinorelbine combination therapy in lung cancer with neuroendocrine differentiation

Introduction: Lung cancer (LC) remains one of the most prevalent and deadly cancers worldwide. Neuroendocrine differentiation (NED) is observed in 25-33% of LC cases. NSCLC patients with NED (NSCLC-NED) often have worse outcomes, resembling SCLC behaviour.

Conference:

Presenting Author:

Authors: Chai M, Zhang Y, Wang Y, Lu Z, Xie J,

Keywords: NSCLC-NED, treatment, surufatinib, vinorelbine,

#3928 MEN1 deficiency-induced the activation of β-Catenin-MGMT axis promotes Pancreatic Neuroendocrine Tumor growth and disrupts the response to Temozolomide

Introduction: O6-methylguanine DNA methyltransferase (MGMT) removes alkyl adducts from the guanine O6 position (O6-MG) and repairs DNA damage. High MGMT expression results in poor response to temozolomide (TMZ).

Conference:

Presenting Author: Ji S

Authors: Ji S, Xu J, Wang F, Lou X, Ye Z,

Keywords: Pancreatic neuroendocrine tumor, MGMT, MEN1, Temozolomide tolerance,